CerviVax
New Generation Therapeutic vaccine for the Treatment of HPV infections and Cervical Dysplasia
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0CerviVax project word cloud
Explore the words cloud of the CerviVax project. It provides you a very rough idea of what is the project "CerviVax" about.
Project "CerviVax" data sheet
The following table provides information about the project.
| Coordinator |
VLP THE VACCINES COMPANY
Organization address contact info |
| Coordinator Country | Spain [ES] |
| Project website | http://www.vlpbio.com |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology) 2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument) |
| Code Call | H2020-SMEINST-1-2015 |
| Funding Scheme | SME-1 |
| Starting year | 2015 |
| Duration (year-month-day) | from 2015-09-01 to 2016-02-29 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | VLP THE VACCINES COMPANY | ES (SALAMANCA) | coordinator | 50˙000.00 |
Map
Project objective
VLPbio (www.vlpbio.com) is a biotechnological company applying immunotherapeutic solutionsto fight and prevent human and animal diseases addressing unmet clinical needs in the main pharmaceutical markets. Our technology is based on patented and proprietary Ch-VLP platform (Chimeric Virus like Particles) derived from the Infectious Bursal Disease Virus (IBDV). Virus-like particles are empty and not infectious viral particles capable of incorporating antigens involved in different pathologies in order to potentiate and direct the humoral or cellular immune response. The potential of the platform to induce both kind of responses has been validated through immunogenic studies and in vivo proofs of concept.
Our business model is to develop innovative vaccines based on our proprietary technological platform up to phase I, where the product will be licensed to a larger biotech or pharmaceutical company
Our main product is Cervivax https://www.dropbox.com/s/p2s06bqm9toai3n/VLPbio.mov?dl=0, an immunotherapeutic vaccine focused on the treatment of cervical dysplasia and infections caused by HPV-16 (Human Papilloma Virus), which is responsible for most of the cases of cervical lesions detected all over the world. Although, there are prophylactic approaches to prevent viral infection, currently do not exist commercial therapeutic solutions to treat infections or lesions caused by the infection, other than surgery combined by chemotherapy. We position our product to cover this unmet need. We have an in vivo efficacy proof of concept of the product with excellent results, overpassing those of other therapies under development in terms of efficacy in absence of any adyuvant (1).
The overall aim of the project that we are submitting is bring Cervivax from the current status up to clinical-phase I, where we are aiming to license it to a large biotech or pharma company. Currently we have two preliminary agreements with 2 leading pharma companies, which are in due diligence phase
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CERVIVAX" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CERVIVAX" are provided by the European Opendata Portal: CORDIS opendata.